Biocon has substantial upsides: Rajesh Jain
"Amongst the Indian tier 2 pharma companies, Biocon is certainly a pick."
By 
|
| Rajesh Jain, Market Strategist in an interview with ET Now talks about Biocon.
What do you make of Biocon?
Biocon has substantial upsides from its forays into diabetes and the Pfizer model, I am not the Pfizer tap, I am not completely updated on that but amongst the Indian tier 2 pharma companies, Biocon is certainly a pick.
What do you make of Biocon?
Biocon has substantial upsides from its forays into diabetes and the Pfizer model, I am not the Pfizer tap, I am not completely updated on that but amongst the Indian tier 2 pharma companies, Biocon is certainly a pick.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
ETMarkets Management Talk | Solar focus is a lucrative opportunity for wires and cables industry: Rajesh Jain, CFO, RR Kabel2024-02-17T06:40:06Z- On a longer horizon or even on a yearly basis, our margins will be in 8% range: Rajesh Jain, RR Kabel2024-01-30T09:11:26Z
- I was a serial failure before becoming successful: Rajesh Jain, Netcore founder2016-10-26T03:22:17Z
ADVERTISEMENT
